# Boron Mood Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/boron-mood-randomized-trial-evidence-review
Category: evidence-review
Summary: Boron Mood Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic 
Last reviewed: 2026-07-04
Reviewed by: Migaku Evidence Review
# Boron Mood Randomized Trial: What the Evidence Says

## Quick Answer

Boron Mood Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Trace Elements and Depressive Symptoms in Coronary Artery Disease: A Systematic Review of Sparse and Predominantly Indirect Evidence | systematic review | 1 | 2026-04-24 | 10.3390/ijms27093805 |
| Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation | preclinical study | 4 | 2026-06-02 | 10.3390/nu18111794 |

## What The Sources Report

- Depressive symptoms frequently co-occur in patients with CAD and are associated with adverse clinical outcomes, including reduced treatment adherence and increased cardiovascular risk. [Baran Jakub Marek (2026); evidence level 1]
- Depression is particularly common following acute coronary events, with reported prevalence rates ranging from approximately 20% to 40%, and has been consistently associated with increased risk of recurrent cardiovascular events and mortality. [Baran Jakub Marek (2026); evidence level 1]
- By interacting with innate pattern recognition receptors (PRRs), including Dectin-1 and Toll-like receptors (TLRs), expressed on gut-associated lymphoid tissue (GALT) and immune cells, β-1,3-glucans regulate both innate and adaptive immune responses. [Samiksha Fnu (2026); evidence level 4]
- Table 2 A summary of β-glucans derived from different fungal sources and their associated therapeutic properties is provided in. [Samiksha Fnu (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For boron mood randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Baran Jakub Marek (2026). Trace Elements and Depressive Symptoms in Coronary Artery Disease: A Systematic Review of Sparse and Predominantly Indirect Evidence. DOI: 10.3390/ijms27093805. PMCID: PMC13164162. PMID: 42123390. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164162/
- Samiksha Fnu (2026). Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. DOI: 10.3390/nu18111794. PMCID: PMC13258535. PMID: 42280437. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258535/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.